Cite
MLA Citation
R J Motzer et al.. “LBA54ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC).” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100097082836.0x000022